DGIdb - CARBAMAZEPINE Drug Record

CARBAMAZEPINE chembl:CHEMBL108 ApprovedImmunotherapy

Alternate Names:

EPITOL
EPIMAZ
TEGRETOL PROLONGED RELEASE
TEGRETOL-XR
TIMONIL 200 RET
CARBAGEN SR
EQUETRO
TERIL
NSC-169864
SIRTAL RET
TERIL RET
G-32883
GEIGY 32883
ARBIL MR
CARBATROL
CARNEXIV
TIMONIL 400 RET
TEGRETOL CHEWTAB
EPIMAZ RET
TEGRETOL XR
CARBAMAZEPINE
TEGRETOL
5-CARBAMOYL-5H-DIBENZ[B,F]AZEPINE
CBZ
5-CARBAMOYL-5H-DIBENZO(B,F)AZEPINE
5-CARBAMYL-5H-DIBENZO(B,F)AZEPINE
5H-DIBENZ(B,F)AZEPINE-5-CARBOXAMIDE
5-CARBAMOYL-5H-DIBENZ(B,F)AZEPINE
CARBAMAZEPEN
CARBAMAZEPINUM
CALEPSIN
TEGRETOL®
CARBAMAZEPINA
CARBAMAZEPIN
CARBAMAZÉPINE
TEG111
pubchem.compound:2554
chemidplus:298-46-4
chembl:CHEMBL108
rxcui:2002
drugbank:00564

Drug Info:

Year of Approval	1968
Drug Class	anticonvulsants
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	for treatment of bipolar disorder
Drug Categories	inducers of drug clearance
Drug Categories	cardiovascular agents
Drug Categories	cytochrome p-450 cyp1a2 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp1a2 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp2b6 substrates
Drug Categories	cytochrome p-450 cyp2c19 inducers (moderate)
Drug Categories	cytochrome p-450 cyp2c19 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp2c8 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp2c9 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp3a inducers (strong)
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 inducers
Drug Categories	cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp3a5 inducers
Drug Categories	cytochrome p-450 cyp3a5 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp3a5 inducers (strong)
Drug Categories	cytochrome p-450 cyp3a5 substrates
Drug Categories	cytochrome p-450 cyp3a5 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 cyp3a7 substrates
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	decreased central nervous system disorganized electrical activity
Drug Categories	drugs that are mainly renally excreted
Drug Categories	drugs that are mainly renally excreted with narrow therapeutic index
Drug Categories	enzyme inducing antiepileptic drugs
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	immunosuppressive agents
Drug Categories	membrane transport modulators
Drug Categories	miscellaneous anticonvulsants
Drug Categories	mood stabilizer
Drug Categories	p-glycoprotein inducers
Drug Categories	p-glycoprotein substrates
Drug Categories	serotonergic drugs shown to increase risk of serotonin syndrome
Drug Categories	sodium channel blockers
Drug Categories	thyroxine-binding globulin substrates
Drug Categories	ugt1a1 inducers
Drug Categories	ugt1a6 inducer
Drug Categories	ugt2b7 substrates

(7 More Sources)

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Djordjevic N et al., 2016, CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy., Eur J Clin Pharmacol
Lipkind et al., 2010, Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore., Mol. Pharmacol.
Yang et al., 2002, Inhibition of Na(+) current by imipramine and related compounds: different binding kinetics as an inactivation stabilizer and as an open channel blocker., Mol. Pharmacol.
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Yang et al., 2010, Lidocaine, carbamazepine, and imipramine have partially overlapping binding sites and additive inhibitory effect on neuronal Na+ channels., Anesthesiology
Himmerich et al., 2005, Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium., Psychopharmacology (Berl.)
Talwar P et al., 2017, Genetic contribution of CYP1A1 variant on treatment outcome in epilepsy patients: a functional and interethnic perspective., Pharmacogenomics J
Grover S et al., 2010, Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy., Pharmacogenomics
Hung SI et al., 2006, Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions., Pharmacogenet Genomics
Zhou BT et al., 2012, Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up., CNS Neurosci Ther
He XJ et al., 2013, Association between the HLA-B*15:02 allele and carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in Han individuals of northeastern China., Pharmacol Rep
Haerian BS et al., 2013, SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis., Pharmacogenomics
Kwan P et al., 2008, Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression., Pharmacogenet Genomics
Ma CL et al., 2014, Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy., Pharmacogenomics
Pirmohamed M et al., 2001, TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients., Neurology
Thorn CF et al., 2011, PharmGKB summary: carbamazepine pathway., Pharmacogenet Genomics
Puranik YG et al., 2013, Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy., Pharmacogenomics
Faucette et al., 2004, Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers., Drug Metab. Dispos.
Kwan P et al., 2011, Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy., Pharmacogenomics
Qu J et al., 2012, ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients., CNS Neurosci Ther
Hung CC et al., 2012, Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization., Pharmacogenomics
Kim WJ et al., 2010, A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy., Pharmacogenet Genomics
Hilger E et al., 2012, Lack of association between ABCC2 gene variants and treatment response in epilepsy., Pharmacogenomics
Sporis D et al., 2013, Lack of association between polymorphism in ABCC2 gene and response to antiepileptic drug treatment in Croatian patients with epilepsy., Coll Antropol
Rädisch S et al., 2014, A comprehensive functional and clinical analysis of ABCC2 and its impact on treatment response to carbamazepine., Pharmacogenomics J
Ufer M et al., 2011, Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy., Pharmacogenet Genomics
Alfirevic et al., 2006, HLA-B locus in Caucasian patients with carbamazepine hypersensitivity., Pharmacogenomics
Kim et al., 2007, A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy., Epilepsy Behav
Gjestad C et al., 2016, 4β-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?, Br J Clin Pharmacol
Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
Zhu X et al., 2014, Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy., Pharmacogenomics
Wang P et al., 2015, Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy., Epilepsy Res
Li LJ et al., 2013, Predictive markers for carbamazepine and lamotrigine-induced maculopapular exanthema in Han Chinese., Epilepsy Res
Usui et al., 2003, Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor., Biol. Pharm. Bull.
Saruwatari J et al., 2014, Pregnane X receptor and hepatocyte nuclear factor 4α polymorphisms are cooperatively associated with carbamazepine autoinduction., Pharmacogenet Genomics
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Isojärvi et al., Effects of carbamazepine therapy on serum sex hormone levels in male patients with epilepsy., Epilepsia
Bonuccelli et al., 1985, Effects of carbamazepine on prolactin secretion in normal subjects and in epileptic subjects., Clin Neuropharmacol
Alfirevic A et al., 2006, Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster., Pharmacogenet Genomics
Schwahn B et al., 2001, Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences., Am J Pharmacogenomics
Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
Tutor-Crespo et al., [A study of some indirect biochemical markers in the evaluation of enzymatic induction caused by antiepileptic drugs]., Rev Neurol
Shen C et al., 2017, Effects of ABCB1, ABCC2, UGT2B7 and HNF4α genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy., Seizure
Pearce RE et al., 2002, Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites., Drug Metab Dispos
Di YM et al., 2009, Structure, function, regulation and polymorphism of human cytochrome P450 2A6., Curr Drug Metab
Restrepo JG et al., 2009, Polymorphic drug metabolism in anaesthesia., Curr Drug Metab
Komatsu T et al., 2000, Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4., Drug Metab Dispos
Kimber-Trojnar Z et al., 2003, Perspectives of losigamone in epilepsy treatment., Pol J Pharmacol
Torchin CD et al., 1996, Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes., Drug Metab Dispos
Kumari R et al., 2011, Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population., Indian J Hum Genet
Schlachter K et al., 2009, A splice site variant in the sodium channel gene SCN1A confers risk of febrile seizures., Neurology
Zhou BT et al., 2012, Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population., Clin Exp Pharmacol Physiol
Bertok S et al., 2017, The association of SCN1A p.Thr1067Ala polymorphism with epilepsy risk and the response to antiepileptic drugs in Slovenian children and adolescents with epilepsy., Seizure
Ma CL et al., 2015, Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy., Pharmacogenomics
Rogawski et al., 2004, The neurobiology of antiepileptic drugs., Nat. Rev. Neurosci.
Daci A et al., 2015, Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, Metabolism and Pharmacoresistance in a Population of Kosovar Albanian Epileptic Patients., PLoS One
Manna I et al., 2011, A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy., Epilepsia
Nakajima Y et al., 2005, Haplotype structures of EPHX1 and their effects on the metabolism of carbamazepine-10,11-epoxide in Japanese epileptic patients., Eur J Clin Pharmacol
Makmor-Bakry M et al., 2009, Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing., Clin Neuropharmacol
Ortells MO et al., 2002, Molecular modelling of the interactions of carbamazepine and a nicotinic receptor involved in the autosomal dominant nocturnal frontal lobe epilepsy., Br J Pharmacol
Bertrand D, 2002, Neuronal Nicotinic Acetylcholine Receptors and Epilepsy., Epilepsy Curr
Di Resta C et al., 2010, Effect of carbamazepine and oxcarbazepine on wild-type and mutant neuronal nicotinic acetylcholine receptors linked to nocturnal frontal lobe epilepsy., Eur J Pharmacol

CARBAMAZEPINE HSPA1L

Interaction Score: 2.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16538175

Sources:
PharmGKB
CARBAMAZEPINE HSPA1A

Interaction Score: 2.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16538175

Sources:
PharmGKB
CARBAMAZEPINE BAG6

Interaction Score: 2.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16538176

Sources:
PharmGKB
CARBAMAZEPINE RALBP1

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21738081

Sources:
PharmGKB
CARBAMAZEPINE EPHX1

Interaction Score: 1.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15692831 22188362 26314341 25495409 19620853

Sources:
PharmGKB
CARBAMAZEPINE PRRC2A

Interaction Score: 0.79

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16538176

Sources:
PharmGKB
CARBAMAZEPINE LTA

Interaction Score: 0.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11294926

Sources:
PharmGKB
CARBAMAZEPINE FZD8

Interaction Score: 0.39

Interaction Types & Directionality:

allosteric modulator

Interaction Info:

Details of the Assay for Interaction Binding affinity for FZD8 cysteine-rich domain (CRD) by SPR analysis.

Specific Action of the Ligand Negative

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology
CARBAMAZEPINE TNFRSF1B

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15565432

Sources:
NCI
CARBAMAZEPINE POU5F1

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CARBAMAZEPINE CYP2A6

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12386121 19702528 19442086 11038165 14704462 8886611

Sources:
PharmGKB
CARBAMAZEPINE SCN1A

Interaction Score: 0.28

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
23859570 21747585 22591328 19289736 20643904 22292851 28753467 22188362 12391287 26314341 15208697 25155934 26555147 20526191 21561445

Sources:
PharmGKB DrugBank ChemblInteractions
CARBAMAZEPINE ABCC2

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21449672 22630058 22188362 20216337 21738081 25155934 22256867 23697249 24567120 21799461 23252947

Sources:
PharmGKB
CARBAMAZEPINE HNF4A

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24384557 28837897

Sources:
PharmGKB
CARBAMAZEPINE HLA-DQB1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24399721

Sources:
PharmGKB
CARBAMAZEPINE HLA-B

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16981842

Sources:
NCI FDA
CARBAMAZEPINE CYP1A1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26951882 21121773

Sources:
PharmGKB
CARBAMAZEPINE GGT1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12402220

Sources:
NCI
CARBAMAZEPINE HLA-DRB1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24399721 23830818

Sources:
PharmGKB
CARBAMAZEPINE CYP2B6

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17638512 21738081 14977870

Sources:
NCI PharmGKB
CARBAMAZEPINE UGT2B7

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21738081

Sources:
PharmGKB
CARBAMAZEPINE PRL

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3191895 3924400

Sources:
NCI
CARBAMAZEPINE SCN5A

Interaction Score: 0.1

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

Trial Name SPD 417, carbamazepine,Equetro, Carbatrol

PMIDs:
20643904 12391287 17139284 17016423 20526191

Sources:
TEND TdgClinicalTrial ChemblInteractions
CARBAMAZEPINE CYP3A5

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12673034 24384557 21738081 18695978 25495409 26421491 23252947

Sources:
NCI PharmGKB
CARBAMAZEPINE SCN2A

Interaction Score: 0.09

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
23859570 18784617 25155934

Sources:
PharmGKB ChemblInteractions
CARBAMAZEPINE MTHFR

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12083967

Sources:
PharmGKB
CARBAMAZEPINE NR1I3

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21738081

Sources:
PharmGKB
CARBAMAZEPINE BGLAP

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17224308

Sources:
NCI
CARBAMAZEPINE CHRNA4

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12110613 15309115 20561518

Sources:
DrugBank
CARBAMAZEPINE CYP2C8

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21738081

Sources:
PharmGKB
CARBAMAZEPINE HLA-A

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
FDA
CARBAMAZEPINE TNF

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15565432 11294926

Sources:
NCI PharmGKB
CARBAMAZEPINE NR1I2

Interaction Score: 0.04

Interaction Types & Directionality:

activator (activating)

Interaction Info:

PMIDs:
21738081 23252947 14977870

Sources:
PharmGKB DrugBank
CARBAMAZEPINE SCN7A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions
CARBAMAZEPINE SCN8A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CARBAMAZEPINE SCN3A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CARBAMAZEPINE SCN11A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CARBAMAZEPINE GABRA1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22591328

Sources:
PharmGKB
CARBAMAZEPINE SCN4A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

PMIDs:
None found

Sources:
ChemblInteractions
CARBAMAZEPINE SCN9A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CARBAMAZEPINE SCN10A

Interaction Score: 0.02

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CARBAMAZEPINE CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300 21738081 26574235 9187528 25495409 26421491 23252947

Sources:
DTC PharmGKB
CARBAMAZEPINE CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300 26762380

Sources:
DTC PharmGKB
CARBAMAZEPINE NR3C1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
CARBAMAZEPINE CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC PharmGKB
CARBAMAZEPINE CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CARBAMAZEPINE CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
CARBAMAZEPINE AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB00564

Version: 5.1.7

Alternate Names:

CARBAMAZEPINE DrugBank Drug Name

298-46-4 CAS Number

Actebral Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Ortells MO et al., 2002, Molecular modelling of the interactions of carbamazepine and a nicotinic receptor involved in the autosomal dominant nocturnal frontal lobe epilepsy., Br J Pharmacol

Bertrand D, 2002, Neuronal Nicotinic Acetylcholine Receptors and Epilepsy., Epilepsy Curr

Di Resta C et al., 2010, Effect of carbamazepine and oxcarbazepine on wild-type and mutant neuronal nicotinic acetylcholine receptors linked to nocturnal frontal lobe epilepsy., Eur J Pharmacol

TEND: CARBAMAZEPINE
- Version: 01-August-2011
Alternate Names:

CARBAMAZEPINE Primary Drug Name

Drug Info:

Drug Class anticonvulsants

Year of Approval 1968

Publications:
TdgClinicalTrial: CARBAMAZEPINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications for treatment of bipolar disorder

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: CARBAMAZEPINE

Version: 14-September-2017

Alternate Names:

C341 NCI drug code

Drug Info:

Publications:

Kim et al., 2007, A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy., Epilepsy Behav

Isojärvi et al., Effects of carbamazepine therapy on serum sex hormone levels in male patients with epilepsy., Epilepsia

Bonuccelli et al., 1985, Effects of carbamazepine on prolactin secretion in normal subjects and in epileptic subjects., Clin Neuropharmacol

DTC: CARBAMAZEPINE
- Version: 02-September-2020
Alternate Names:

CHEMBL108 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

PharmGKB: carbamazepine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Djordjevic N et al., 2016, CYP1A2 genotype affects carbamazepine pharmacokinetics in children with epilepsy., Eur J Clin Pharmacol

Talwar P et al., 2017, Genetic contribution of CYP1A1 variant on treatment outcome in epilepsy patients: a functional and interethnic perspective., Pharmacogenomics J

Grover S et al., 2010, Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy., Pharmacogenomics

GuideToPharmacology: 178102003
- Version: 29-September-2020
Alternate Names:

CARBAMAZEPINE GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Carbamazepine
- Version: 2020.06.01
Alternate Names:

D04MSM TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL108
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL108
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
FDA: Carbamazepine
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Details of the Assay for Interaction	Binding affinity for FZD8 cysteine-rich domain (CRD) by SPR analysis.
Specific Action of the Ligand	Negative
Endogenous Drug?	False

Mechanism of Interaction	Sodium channel alpha subunit blocker
Direct Interaction	yes

CARBAMAZEPINE	DrugBank Drug Name
298-46-4	CAS Number
Actebral	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

blocker (inhibitory)
inhibitor (inhibitory)

CARBAMAZEPINE Drug Record

CARBAMAZEPINE chembl:CHEMBL108 ApprovedImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16538175

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16538175

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16538176

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21738081

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15692831 22188362 26314341 25495409 19620853

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16538176

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11294926

Sources: PharmGKB

Interaction Types & Directionality: allosteric modulator

Interaction Info: Details of the Assay for Interaction Binding affinity for FZD8 cysteine-rich domain (CRD) by SPR analysis. Specific Action of the Ligand Negative Endogenous Drug? False

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15565432

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12386121 19702528 19442086 11038165 14704462 8886611

Sources: PharmGKB

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Sodium channel alpha subunit blocker Direct Interaction yes

PMIDs: 23859570 21747585 22591328 19289736 20643904 22292851 28753467 22188362 12391287 26314341 15208697 25155934 26555147 20526191 21561445

Sources: PharmGKB DrugBank ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21449672 22630058 22188362 20216337 21738081 25155934 22256867 23697249 24567120 21799461 23252947

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24384557 28837897

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24399721

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16981842

Sources: NCI FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26951882 21121773

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12402220

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24399721 23830818

Interaction Types & Directionality:

n/a

PMIDs:
16538175

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16538175

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16538176

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21738081

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15692831 22188362 26314341 25495409 19620853

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16538176

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11294926

Sources:
PharmGKB

Interaction Types & Directionality:

allosteric modulator

Interaction Info:

Details of the Assay for Interaction Binding affinity for FZD8 cysteine-rich domain (CRD) by SPR analysis.

Specific Action of the Ligand Negative

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
15565432

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12386121 19702528 19442086 11038165 14704462 8886611

Sources:
PharmGKB

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
23859570 21747585 22591328 19289736 20643904 22292851 28753467 22188362 12391287 26314341 15208697 25155934 26555147 20526191 21561445

Sources:
PharmGKB DrugBank ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
21449672 22630058 22188362 20216337 21738081 25155934 22256867 23697249 24567120 21799461 23252947

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24384557 28837897

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24399721

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16981842

Sources:
NCI FDA

Interaction Types & Directionality:

n/a

PMIDs:
26951882 21121773

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
12402220

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
24399721 23830818

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17638512 21738081 14977870

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21738081

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
3191895 3924400

Sources:
NCI

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction yes

Mechanism of Interaction Sodium channel alpha subunit blocker

Trial Name SPD 417, carbamazepine,Equetro, Carbatrol

PMIDs:
20643904 12391287 17139284 17016423 20526191

Sources:
TEND TdgClinicalTrial ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
12673034 24384557 21738081 18695978 25495409 26421491 23252947

Sources:
NCI PharmGKB

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Mechanism of Interaction Sodium channel alpha subunit blocker

Direct Interaction yes

PMIDs:
23859570 18784617 25155934

Sources:
PharmGKB ChemblInteractions

Interaction Types & Directionality:

n/a